TAMPA, Fla., July 16, 2026
PainTEQ has unveiled new scientific evidence supporting its cortical-piercing posterior sacroiliac (SI) joint fixation strategy during the American Society of Pain and Neuroscience (ASPN) 2026 Annual Conference. The presentations combine anatomical, biomechanical, and real-world clinical data that strengthen the scientific foundation for the company’s TRAQ™ and LINQ® technologies, designed to treat patients suffering from chronic sacroiliac joint dysfunction. The findings reinforce the effectiveness of posterior minimally invasive SI joint procedures, highlighting improved fixation characteristics, encouraging patient outcomes, and the potential to advance evidence-based treatment options for chronic pain management. The latest research underscores PainTEQ’s ongoing commitment to expanding physician education, improving procedural outcomes, and advancing innovation in medical technology for musculoskeletal disorders.
PRADA Study Validates Cortical-Piercing Fixation Strategy
A key scientific presentation at ASPN 2026 featured the PainTEQ Real-world Anatomical Data Analysis (PRADA) Study, the first large-scale CT imaging-based investigation evaluating cortical bone thickness within the sacroiliac joint. Researchers analyzed high-resolution CT scans and demonstrated that the 2.5 mm cortical-piercing fixation ridges used in the TRAQ™ procedure consistently exceeded the maximum cortical bone thickness measured across every demographic subgroup. These findings confirm that the implant reliably penetrates both the sacral and iliac cortices, providing the first quantitative anatomical evidence supporting the cortical-piercing fixation strategy. According to investigators, the results validate the engineering design of the TRAQ™ system while offering clinicians stronger scientific confidence in achieving stable fixation across a broad range of patient anatomies. The anatomical evidence further strengthens the rationale for adopting posterior SI joint procedures as an effective minimally invasive treatment for chronic SI joint dysfunction.
Biomechanical and Clinical Data Demonstrate Improved Stability
Complementing the anatomical findings, PainTEQ also presented a finite element biomechanical analysis demonstrating superior resistance to implant micromotion and enhanced fixation performance for both the TRAQ™ and LINQ® procedures compared with other commonly used posterior implant designs. The biomechanical evidence suggests improved implant stability and stronger fixation through cortical engagement of both pelvic structures, an important factor in long-term procedural success. Investigators additionally shared preliminary real-world multicenter clinical data involving 154 patients treated across 61 clinical sites during the limited commercial release of the TRAQ™ procedure. Early clinical experience reported no device-related or procedure-related adverse events while showing encouraging improvements in patient-reported pain outcomes following treatment. Together, the anatomical validation, engineering simulations, and multicenter clinical experience provide converging scientific evidence supporting the effectiveness and safety profile of PainTEQ’s posterior fixation technologies.
Advertisement
Strengthening Evidence for Minimally Invasive SI Joint Procedures
The ASPN 2026 scientific presentations also included comparative research evaluating posterior versus lateral minimally invasive sacroiliac joint procedures using propensity-matched analyses alongside additional biomechanical investigations examining posterior fixation techniques. Collectively, these studies contribute to a growing body of clinical evidence supporting posterior SI joint interventions as an effective option for patients experiencing chronic sacroiliac joint pain. PainTEQ emphasized that continued investment in clinical research, physician education, and evidence generation remains central to its mission of advancing minimally invasive pain management technologies. Ongoing research initiatives are expected to further characterize the long-term safety, procedural performance, and patient outcomes associated with the TRAQ™ platform. By combining robust anatomical validation, advanced biomechanical modeling, and expanding real-world clinical experience, PainTEQ continues to strengthen its leadership in minimally invasive medical devices for chronic pain treatment while providing physicians with scientifically supported technologies that may improve procedural confidence, patient mobility, and overall quality of life for individuals affected by sacroiliac joint dysfunction.
Source: PainTEQ press release
